Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Werewolf Therapeutics (HOWL) EBITDA (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed EBITDA for 5 consecutive years, with -$15.7 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA rose 8.16% to -$15.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$71.6 million, a 8.15% decrease, with the full-year FY2024 number at -$73.6 million, down 81.7% from a year prior.
  • EBITDA was -$15.7 million for Q3 2025 at Werewolf Therapeutics, up from -$17.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$6.1 million in Q2 2023 to a low of -$20.3 million in Q4 2024.
  • A 5-year average of -$14.3 million and a median of -$15.0 million in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: skyrocketed 59.48% in 2023, then plummeted 212.51% in 2024.
  • Werewolf Therapeutics' EBITDA stood at -$17.9 million in 2021, then grew by 26.31% to -$13.2 million in 2022, then increased by 1.65% to -$13.0 million in 2023, then crashed by 56.98% to -$20.3 million in 2024, then grew by 22.71% to -$15.7 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's EBITDA are -$15.7 million (Q3 2025), -$17.5 million (Q2 2025), and -$18.0 million (Q1 2025).